Interestingly, blood detection of a low number of TP53 variant sequences may be due to circulating tumor DNA (e.g., metastatic tumors) or clonal hematopoiesis, which relies on somatic TP53 alterations which benefit hematopoietic stem cells, highlighting the complexity of mosaic variants in TP53 [58]. This evidence concerns the gene TP53 and neoplasm.